Login to Your Account



SIDE EFFECTS VEX 'VALEANT' EFFORT IN FSD

Addyi sugar daddy touts Sprout in $1B deal, but no drink stink on Palatin's phase III BM

By Randy Osborne
Staff Writer

Friday, August 21, 2015
Palatin Technologies Inc. CEO Carl Spana told BioWorld Today his firm is "seeing a lot of interest coming in" as a result of Valeant Pharmaceuticals International Inc.'s plan to buy out Sprout Pharmaceuticals Inc. for about $1 billion, bringing aboard Addyi (flibanserin), the drug for hypoactive sexual desire disorder (HSDD) approved by the FDA earlier this week.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription